Scripps researchers discovered a new set of antibodies (blue and gray) that can neutralize influenza by binding to the anchor region of influenza HA (pink and purple).
Credit: Julianna Han, Ward Lab
A new antibody discovered in the blood of some people vaccinated against or infected with influenza can recognize a broad variety of flu viruses.
Scientists at Scripps Research, University of Chicago and Icahn School of Medicine at Mount Sinai have identified a new Achilles’ heel of influenza virus, making progress in the quest for a universal flu vaccine. Antibodies against a long-ignored section of the virus, which the team dubbed the anchor, have the potential to recognize a broad variety of flu strains, even as the virus mutates from year to year, they reported Dec. 23, 2021 in the journal Nature.
“It’s always very exciting to discover a new site of vulnerability on a virus because it paves the way for rational vaccine design,” says co-senior author Andrew Ward, PhD, professor of Integrative Structural and Computational Biology at Scripps Research. “It also demonstrates that despite all the years and effort of influenza vaccine research there are still new things to discover.”
“By identifying sites of vulnerability to antibodies that are shared by large numbers of variant influenza strains we can design vaccines that are less affected by viral mutations,” says study co-senior author Patrick Wilson, MD, who was previously at the University of Chicago and recently recruited to Weill Cornell Medicine as a professor of pediatrics and a scientist in the institution’s Gale and Ira Drukier Institute for Children’s Health. “The anchor antibodies we describe bind to such a site. The antibodies themselves can also be developed as drugs with broad therapeutic applications.”
In a typical year, influenza affects more than 20 million people in the United States and leads to more than 20,000 deaths. Vaccines against influenza typically coax the immune system to generate antibodies that recognize the head of hemagglutinin (HA), a protein that extends outward from the surface of the flu virus. The head is the most accessible regions of HA, making it a good target for the immune system; unfortunately, it is also one of the most variable. From year to year, the head of HA often mutates, necessitating new vaccines.
Researchers have designed experimental influenza vaccines to be more universal, spurring the body to create antibodies against the less-variable stalk region of HA, which extends like a stem between the influenza virion and the HA head. Some of these universal flu vaccines are currently in early clinical trials.
In the new study, a collaborative team of scientists characterized 358 different antibodies present in the blood of people who had either been given a seasonal influenza vaccine, were in a phase I trial for an experimental, universal influenza vaccine, or had been naturally infected with influenza.
Many of the antibodies present in the blood of participants were antibodies already known to recognize either the HA head or stalk. But a collection of new antibodies stood out; the antibodies bound to the very bottom of the stalk, near where each HA molecule is attached to the membrane of the flu virion.
The co-first authors of the manuscript—Julianna Han, a staff scientist in the Ward lab, and Jenna Guthmiller, a postdoctoral fellow at the University of Chicago—named this section of HA the anchor, and began studying it further. In all, the scientists identified 50 different antibodies to the HA anchor, from a total of 21 individuals. The antibodies, they discovered, recognized a variety of H1 influenza viruses, which account for many seasonal flu strains. Some of the antibodies were also able to recognize pandemic H2 and H5 strains of influenza in lab tests. And in mice, the antibodies successfully protected against infection by three different H1 influenza viruses.
“In order to increase our protection to these highly mutating viruses, we need to have as many tools as we can,” says Han. “This discovery adds one more highly potent target to our repertoire.” Importantly, these antibodies appear to be fairly common in people, and belong to a class of antibodies that any person’s body can produce—an important consideration in designing a vaccine to spur their development.
“The human immune system already has the ability to make antibodies to this epitope, so it’s just a matter of applying modern protein engineering methods to make a vaccine that can induce those antibodies in sufficient numbers,” adds Guthmiller.
The researchers say that future, improved iterations of a universal vaccine could more purposefully aim to generate anchor antibodies. Until now, scientists designing universal vaccines hadn’t paid attention to whether the anchor region of the stem was included as a target. Ideally, a universal influenza vaccine will lead to antibodies against multiple sections of the virus—such as both the HA anchor and the stalk—to increase protection to evolving viruses.
The researchers are planning future studies on how to design a vaccine that most directly targets the HA anchor of different influenza strains.
Original Article: No more annual flu shot? Scripps Research and collaborators find new target for universal influenza vaccine
More from: The Scripps Research Institute | University of Chicago | Icahn School of Medicine at Mount Sinai | University of Innsbruck | Fred Hutchinson Cancer Research Center | University of Maryland School of Medicine
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Universal influenza vaccine
- Swine Flu News
Universal Flu Vaccine Protects Against Variants of Both Influenza A and B Viruses, Researchers Find Aug. 25, 2022 — A new universal flu vaccine protects against diverse variants of both ...
- New influenza vaccine strategies aim to enhance protection with T-cell responses
A recent review highlights the need for innovative influenza vaccines that combine T-cell and antibody responses to enhance protection across multiple strains and seasons.
- New Strategy Could Lead to Universal, Long-Lasting Flu Shot
Duke researchers have opened a new avenue in the attack against influenza viruses by creating a vaccine that encourages the immune system to target a portion of the virus surface that is less variable ...
- New Strategy Could Lead to Universal, Long-Lasting Flu Shot
This new vaccine approach, described May 1 in the journal Science Translational Medicine, is part of a 5-year-old effort to develop a longer-lasting universal flu vaccine that would be able to foil ...
- Vaccine Developers Leverage mRNA and Other Powerful Technologies
The company’s first program is for a universal influenza vaccine. Alexandre Le Vert Co-Founder and CEO, Osivax One of the biggest hurdles in vaccine development is creating vaccines that are highly ...
Go deeper with Google Headlines on:
Universal influenza vaccine
[google_news title=”” keyword=”universal influenza vaccine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Universal flu vaccine
- Swine Flu News
Universal Flu Vaccine Protects Against Variants of Both Influenza A and B Viruses, Researchers Find Aug. 25, 2022 — A new universal flu vaccine protects against diverse variants of both ...
- New strategy could lead to universal, long-lasting flu shot
An experimental influenza vaccine carrying more than 80,000 variations of hemagglutinin antigens caused the immune system of mice and ferrets to respond more strongly to less variable portions of the ...
- Unlocking Lifetime Flu Protection: Duke’s Innovative Vaccine Strategy
Experimental vaccine targets portions of the flu virus that don’t change. Duke researchers have opened a new avenue in the attack against influenza viruses by creating a vaccine that encourages the ...
- New vaccine approach shows promise in targeting less variable region of influenza virus
Even with vaccines, influenza kills about a half-million people each year around the world. This new vaccine approach, described May 1 in the journal Science Translational Medicine, is part of a ...
- No More Yearly Flu Shots? Vaccine Mixed From 80,000 Proteins Could Be The Key
The two major surface proteins on an influenza virus are called hemagglutinin and neuraminidase ... and human trials would of course be needed before you could rock up to Walgreens and get your ...
Go deeper with Google Headlines on:
Universal flu vaccine
[google_news title=”” keyword=”universal flu vaccine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]